Increased Drug Resistance
2
Pipeline Programs
5
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
NovartisBASEL, Switzerland
1 programChange in Ocular Flora Resistance From Repeated Topical Antibiotic UseN/A
SandozAustria - Kundl
1 programChange in Ocular Flora Resistance From Repeated Topical Antibiotic UseN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Hanmi PharmaceuticalNOV120101
SandozChange in Ocular Flora Resistance From Repeated Topical Antibiotic Use
Clinical Trials (2)
Total enrollment: 240 patients across 2 trials
NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors
Start: Jan 2013Est. completion: Sep 201440 patients
Phase 2Completed
Change in Ocular Flora Resistance From Repeated Topical Antibiotic Use
Start: Jun 2010Est. completion: Dec 2011200 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
5 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.